Business Context and Reporting Period
This Form 8-K is filed by EyeGate Pharmaceuticals, Inc. (noted as Kiora Pharmaceuticals Inc. in metadata) for the reporting period ending September 20, 2018. The filing addresses a regulatory matter concerning the company's continued listing on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on compliance with listing standards rather than financial performance metrics.
Material Changes and Listing Status
- Initial Non-Compliance: On March 20, 2018, the company received notice from Nasdaq regarding non-compliance with the minimum bid price requirement (Rule 5550(a)(2)), which mandates a closing bid price of at least $1.00 for 10 consecutive business days.
- Extension Granted: On September 20, 2018, Nasdaq issued an Extension Letter granting an additional 180-day compliance period, extending until March 18, 2019.
- Basis for Extension: The extension was granted because the company met all other initial listing requirements, including the market value of publicly held shares, and submitted a written notice of intent to cure the deficiency, potentially via a reverse stock split.
Outlook, Risks, and Management Commentary
- Delisting Risk: If the company fails to regain compliance by March 18, 2019, Nasdaq will determine to delist the common stock. The company would have the opportunity to appeal this determination to a hearings panel, though success is not assured.
- Management Action: Management intends to monitor the closing bid price and may implement available options, such as a reverse stock split, to regain compliance.
- Current Status: The company remains listed on Nasdaq pending the outcome of the compliance period.
Investor Verification Checklist
- Verify the current closing bid price of the company's common stock to assess proximity to the $1.00 threshold.
- Confirm whether the company has announced a specific plan or timeline for a reverse stock split.
- Monitor future filings for any updates on the compliance status before the March 18, 2019 deadline.
- Review the press release filed as Exhibit 99.1 for additional details on the extension.